Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Andrew Kent, MD PhD, Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138832

Published: 2020

Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-136120

Published: 2020

Journal Articles

Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy

Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-138821

Published: 2020

Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 1311.

https://doi.org/10.1182/blood-2019-127418

Published: 2019

Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Jonathan A Gutman, MD, Prashant Sharma, MD, Enkhtsetseg Purev, MD, Clayton Smith, MD, Amanda Winters, MD PhD, Andrew Hammes, MS, Michael R. Loken, PhD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 4615.

https://doi.org/10.1182/blood-2019-129150

Published: 2019

Journal Articles

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Blood (2019) 134 (Supplement_1): 185.

https://doi.org/10.1182/blood-2019-131390

Published: 2019

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine

Diana Abbott, PhD, Andrew Hammes, MS, Jonathan A Gutman, MD, Daniel A Pollyea, MD, Clayton Smith, MD

Blood (2019) 134 (Supplement_1): 5897.

https://doi.org/10.1182/blood-2019-126344

Published: 2019

Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Blood (2019) 134 (Supplement_1): 2638.

https://doi.org/10.1182/blood-2019-122120

Published: 2019

Journal Articles

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Daniel A Pollyea, MD, Courtney L Jones, PhD, Brett M Stevens, PhD, Shanshan Pei, PhD, Angelo D'Alessandro, PhD, Rachel Culp-Hill, BS, Diana Abbott, PhD, Andrew Hammes, MS, James Dugan, MD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 432.

https://doi.org/10.1182/blood-2018-99-111507

Published: 2018

Journal Articles

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

Prashant Sharma, MD, Enkhtsetseg Purev, MD PhD, Bradley M. Haverkos, MD MPH, MS, Daniel A Pollyea, MD, Clayton Smith, MD, Manali Kamdar, Daniel W Sherbenou, MD PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 4660.

https://doi.org/10.1182/blood-2018-99-119690

Published: 2018

Journal Articles

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Zachary J Walker, MS, Michael J VanWyngarden, BS, Brett M Stevens, PhD, Christophe Langouët-Astrie, MS, Clayton Smith, MD, Brent E Palmer, PhD, Peter A Forsberg, MD, Tomer M Mark, MD MS, Craig T Jordan, PhD, Daniel W Sherbenou, MD PhD

Blood (2018) 132 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2018-99-111394

Published: 2018

Journal Articles

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

Courtney L Jones, PhD, Brett M Stevens, PhD, Angelo D'Alessandro, PhD, Julia Reisz, PhD, Rachel Culp-Hill, BS, Travis Nemkov, Shanshan Pei, PhD, Nabilah Khan, Biniam Adane, PhD, Haobin Ye, PhD, Dominik Reinhold, Clayton Smith, MD, James DeGregori, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2018-99-111965

Published: 2018

Journal Articles

Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant

Amanda Winters, MD PhD, Madeline Goosman, Brett M Stevens, PhD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Daniel A Pollyea, MD, Craig T Jordan, PhD, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 2138.

https://doi.org/10.1182/blood-2018-99-110834

Published: 2018

Journal Articles

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Daniel A. Pollyea, MD, Brett M. Stevens, PhD, Amanda Winters, MD PhD, Mohd Minhajuddin, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD FRCPC, Diana Abbott, PhD, Craig T. Jordan, PhD

Blood (2017) 130 (Supplement 1): 181.

https://doi.org/10.1182/blood.V130.Suppl_1.181.181

Published: 2017

Journal Articles

Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes

Zohra Nooruddin, MD, Zenggang Pan, MD PhD, Lilyana Gross, Weitzenkamp David, Bradley M. Haverkos, MD MPH, MS, Daniel A Pollyea, MD, Jonathan A Gutman, MD, William Robinson, MD PhD, Clayton Smith, MD FRCPC, Jeffrey Schowinsky, MD, Purev Enkhtsetseg, MD, Daniel W. Sherbenou, MD PhD, Rachel Rabinovitch, MD, Douglas Ney, MD, Craig T Jordan, PhD, Manali Kamdar, MD

Blood (2016) 128 (22): 3054.

https://doi.org/10.1182/blood.V128.22.3054.3054

Published: 2016

Journal Articles

IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience

Zohra Nooruddin, MD, William Robinson, MD PhD, Daniel Pollyea, MD MS, Jonathan A Gutman, MD, Clayton Smith, MD FRCPC, Zenggang Pan, MD, Craig T Jordan, PhD, Rachel Rabinovitch, MD, Jeffrey Schowinsky, Xian Lu, PhD, Douglas Ney, MD, Manali Kamdar, MD

Blood (2015) 126 (23): 1443.

https://doi.org/10.1182/blood.V126.23.1443.1443

Published: 2015

Journal Articles

Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (<12 months).

Christopher P. Venner, BSc, MD, Joseph M. Connors, MD, Heather J. Sutherland, MD, PhD, John D. Shepherd, MD, Linda Hamata, Yasser Abou Mourad, MD, Michael J Barnett, BMBS, Donna L. Forrest, MD, Donna E. Hogge, MD, PhD, Stephen H. Nantel, MD, FRCPC, Sujaatha Narayanan, Thomas J. Nevill, MD, FRCPC, Janet Nitta, Maryse M Power, Cynthia L. Toze, MD, FRCP(C), Clayton Smith, MD, FRCPC, Kevin Song, MD

Blood (2009) 114 (22): 2872.

https://doi.org/10.1182/blood.V114.22.2872.2872

Published: 2009

Journal Articles

Short Progression Free Survival Post Non-Myeloablative Sibling Allogeneic Stem Cell Transplantion for Multiple Myeloma.

Kevin Song, MD, Heather J. Sutherland, MD, PhD, John D. Shepherd, MD, Yasser Abou Mourad, MD, Michael J Barnett, BM, Donna L. Forrest, MD, Donna E. Hogge, MD, PhD, Sujaatha Narayanan, MBBS, Stephen H. Nantel, MD, Maryse M Power, MB, Cynthia L. Toze, MD, Clayton Smith, MD, Thomas J. Nevill, MD

Blood (2009) 114 (22): 4323.

https://doi.org/10.1182/blood.V114.22.4323.4323

Published: 2009

Journal Articles

High Incidence of Invasive Fungal Infections in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.

Winnie Ma, BSc(Pharm), Dawn Warkentin, BSc(Pharm), PharmD, Janice Yeung, BSc(Pharm), PharmD, John D Shepherd, MD, Yasser Abou Mourad, MD, Clayton Smith, MD, FRCPC, Kevin Song, MD, Donna E. Hogge, MD, PhD, Michael J Barnett, BMBS, Thomas J. Nevill, MD, FRCPC, Stephen H. Nantel, MD, FRCPC, Cynthia L. Toze, MD, FRCP(C), Heather J. Sutherland, MD, PhD, Donna L. Forrest, MD, Sujaatha Narayanan, MD, Maryse M Power, MD

Blood (2009) 114 (22): 1136.

https://doi.org/10.1182/blood.V114.22.1136.1136

Published: 2009

NARROW

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes

IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience

Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (<12 months).

Short Progression Free Survival Post Non-Myeloablative Sibling Allogeneic Stem Cell Transplantion for Multiple Myeloma.

High Incidence of Invasive Fungal Infections in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only